Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
What's Your Reaction?
